Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference January 2026
11 slides from Immuron's conference presentation, Jan 23, 2026
Slide 1: Immuron CEO presentation at Emerging Growth Conference
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, January 23, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference on Thursday 22nd January
Slide 2: For personal use only
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits direc
Slide 3: References and forward-looking statements
Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected.
Slide 4: Emerging Growth Conference January 2026
For personal use only EMERGING GROWTH CONFERENCE 23 JANUARY 2026 NASDAQ: IMRN ASX: IMC 1
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Immuron company overview
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases For personal use only Technology Research & Technology Platform Platform Global Corporate Development Safe and pot
Slide 7: FY25 Financial Achievements
FY25 Financial Achievements For personal use only Global Sales Australian Sales North American Revenue Revenue Sales Revenue $7.3m $5.3m $2.0m Up 49% Up 40% Up 76% EBITDA (ex-R&D)1 Gross Profit Cash + Term $(3.1)m Margin Deposit 2,3 $2.1m 65.4% $5.9m improvement 1 ex-R&D: add back research & develop
Slide 8: Travelan continued strong sales growth
Travelan® continued strong sales growth Global Year to Date Net Sales ($AUD) Global $8,000,000 For personal use only $7,000,000 + FY2025 AUD$7.3 million up 49% on prior year $6,000,000 + FY2026 H1 AUD$4.2 million up 5% on FY2025 H1 $5,000,000 $4,000,000 $3,000,000 $2,000,000 Australia $1,000,000 FY2
Slide 9: FY25 Clinical Achievements and Operational Highlights
FY25 Clinical Achievements and Operational Highlights For personal use only Travelan® Ph 2 FDA approval Travelan® statistically IMM-529 n=851 trial significant IND completed results1 Updated peak New research New product U.S. sales for collaboration launch in IMM-529 IMM-986 (VRE) Australia US$400 m
Slide 10: FY26 Outlook
FY26 Outlook For personal use only Progression Continued YoY towards EBITDA sales growth (ex-R&D)1 breakeven Travelan® IMM-986 (VRE) IMM-529 End of Phase 2 Pre-clinical data Initiation of Phase 2 Meeting with FDA 1H 2026 1H 2026 1H 2026 1 ex-R&D: add back research & development, less R&D Tax Incenti
Slide 11: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 IMMURON INVESTOR HUB COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH